Aquestive Therapeutics (AQST) Non Operating Interest Expenses (2017 - 2026)

Aquestive Therapeutics has reported Non Operating Interest Expenses for 10 years, with the latest figure at $2.8 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 0.93% year-over-year to $2.8 million in Q2 2026; TTM through Jun 2026 was $11.3 million, a 1.3% increase from a year earlier, with the FY2025 full-year figure at $11.1 million, changed 0.02% from the prior year.
• Non Operating Interest Expenses was $2.8 million for Q2 2026 at Aquestive Therapeutics, down from $2.9 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $2.9 million in Q1 2026, with the low at $1.3 million in Q3 2023.
• Average Non Operating Interest Expenses over 5 years is $2.3 million, with a median of $2.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses slumped 41.4% in 2022, then surged 121.34% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $1.6 million in 2022, then surged by 37.76% to $2.3 million in 2023, then advanced by 22.26% to $2.8 million in 2024, then retreated by 0.04% to $2.8 million in 2025, then advanced by 1.04% to $2.8 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.8 million (Q2 2026), $2.9 million (Q1 2026), and $2.8 million (Q4 2025), per Business Quant data.